A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment

Trial Profile

A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Verinurad (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 30 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 12 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Jan 2016, according to ClinicalTrails.gov.record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top